Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Christopher J D Wallis; Zachary Klaassen; William C Jackson; Robert T Dess; Zachery R Reichert; Yilun Sun; Daniel E Spratt

doi:10.1001/jamanetworkopen.2021.10950

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

JAMA Netw Open. 2021 May 3;4(5):e2110950. doi: 10.1001/jamanetworkopen.2021.10950.

Authors

Christopher J D Wallis¹, Zachary Klaassen^{2

3}, William C Jackson⁴, Robert T Dess⁴, Zachery R Reichert⁵, Yilun Sun^{4

6}, Daniel E Spratt^{4

7}

Affiliations

¹ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Surgery, Division of Urology, Medical College of Georgia at Augusta University, Augusta.
³ Georgia Cancer Center, Augusta University, Augusta.
⁴ Department of Radiation Oncology, University of Michigan, Ann Arbor.
⁵ Department of Medicine, University of Michigan, Ann Arbor.
⁶ Department of Biostatistics, University of Michigan, Ann Arbor.
⁷ Department of Radiation Oncology, University Hospitals, Case Western Reserve University, Cleveland, Ohio.

Abstract

This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.

Publication types

Comparative Study
Randomized Controlled Trial

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Humans
Male
Middle Aged
Neoplasm Metastasis / drug therapy*
Phthalazines / therapeutic use*
Piperazines / therapeutic use*
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Taxoids / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Phthalazines
Piperazines
Taxoids